Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support

A three-arm randomized controlled non-inferiority pilot study comparing anticoagulation strategies using unfractionated heparin, argatroban and enoxaparin for extracorporeal membrane oxygenation support conducted as an investigator-initiated, prospective, parallel group, open-label, active comparator controlled, single center, phase IV study to evaluate the non-inferiority of enoxaparin or argatroban for anticoagulation during ECMO therapy in comparison to the current standard, unfractionated heparin, as measured by the incidence of thromboembolic events during the duration of ECMO therapy

NCT Number	NCT06442267
Lead Sponsor	Medical University of Vienna
Conditions	Respiratory Insufficiency, Circulatory Failure, Thromboembolism, Bleeding
Enrollment	90 participants
Start Date	2024-07-30
Primary Completion	2027-01-30 (estimated)
Study Completion	2027-07-30 (estimated)
Updated on ClinicalTrials.gov	2024-10-29